


Figure 1. NRG-GI008 SCHEMA



^{*}Patients with completely resected stages II or IIIC colon cancer who are ctDNA +ve as determined by a SignateraTM ctDNA test performed outside of the trial through routine clinical care and who otherwise meet all eligibility criteria for Step 1-Registration are eligible for enrollment into Cohort B.

Version Date: February 01, 2022

^{**}Patients in Cohort A (Arm 2) who develop a ctDNA +ve assay during serial monitoring may transition to the ctDNA+ve cohort (Cohort B) and undergo a second randomization.